Overexpression of FUS and PRDX5 Genes In Multiple Myeloma Patients


Suer İ. , Aday A. , Sariman M., Ayer M., Yönal Hindilerden İ. , Sırma Ekmekci S. , ...More

14. Ulusal Tıbbi Genetik Kongresi (Uluslararası katılımlı), İstanbul, Turkey, 20 - 23 November 2020, pp.23

  • Publication Type: Conference Paper / Summary Text
  • City: İstanbul
  • Country: Turkey
  • Page Numbers: pp.23

Abstract

Objective: Multiple myeloma is a hematopoietic malignancy characterized by the clonal proliferation of plasma cells. We

evaluated our previous RNA-sequencing project’s (Project ID:7348) data of the gene expression profiles of bone marrow

myeloma cells in multiple myeloma patients.

Materials-Methods: Assessment of data from the aforementioned study revealed that the PTPN6, FUS, CD74, MS4A3, PRDX5

and UNC45B genes were found to be expressed at significantly different levels compared to control samples. These genes are

associated with certain pathways such as signal transduction, immunological system and cellular response. In the present study

we aimed to confirm the expression levels of these genes in patients with multiple myeloma (n=50) by the qRT-PCR technique.

Results: No statistically significant difference was found in the PTPN6, CD74, MS4A3 and UNC45B genes between the patient

group (n=50) and the control group (n=16). However, FUS and PRDX5 gene expressions were significantly higher in the patient

group than the control group.

Conclusion: Considering the functions of FUS and PRDX5 genes and their importance in cancer, it is thought that these genes

may shed light on new treatment options for multiple myeloma.

This work was supported by the Scientific Research Projects Coordination Unit of Istanbul University (Project ID:24651).

Keywords: Multiple Myeloma, Pathway and Expression Analysis